We believe that, amid widespread market volatility over the past 18 months, scientific advancements across private biotech continue unabated.
A new age of innovation is fueling breakthroughs across biotech, and we believe private companies are at the forefront of this progress. Immunomodulatory therapies, precision oncology, antibody drug conjugates (ADCs), radiopharmaceuticals, genetic medicines, and a range of other novel treatment modalities are poised to fundamentally change the standard of care for patients around the globe over the next decade. We believe that, amid widespread market volatility over the past 18 months, scientific advancements across private biotech continue unabated. In this piece, we share our views on some of the top innovations we’re tracking in the private biotech market.